Patient harboring a novelPIK3CApoint mutation after acquired resistance to crizotinib in an adenocarcinoma withROS1rearrangement: A case report and literature review-Reference-Cited by-全球学者库

Patient harboring a novelPIK3CApoint mutation after acquired resistance to crizotinib in an adenocarcinoma withROS1rearrangement: A case report and literature review

Published:2017-08-28 Issue:6 Volume:8 Page:714-719
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Xu Chun-wei¹^ORCID,Wang Wen-xian²,Huang Rong-fang¹,He Cheng¹,Liao Xing-hui³,Zhu You-cai⁴,Du Kai-qi⁴,Zhuang Wu⁵,Chen Yan-ping¹,Chen Gang¹,Fang Mei-yu⁶

Affiliation:

1. Department of Pathology, Fujian Provincial Cancer Hospital; Fujian Medical University Cancer Hospital; Fuzhou China

2. Department of Chemotherapy; Zhejiang Cancer Hospital; Hangzhou China

3. Department of Tumor Molecular Laboratory; Zhejiang Rongjun Hospital; Jiaxing China

4. Department of Thoracic Disease Center; Zhejiang Rongjun Hospital; Jiaxing China

5. Department of Medical Thoracic Oncology, Fujian Provincial Cancer Hospital; Fujian Medical University Cancer Hospital; Fuzhou China

6. Department of Comprehensive Medical Oncology; Zhejiang Cancer Hospital; Hangzhou China

Funder

Medical Scientific Research Foundation of Zhejiang Province of China

National Clinical Key Specialty Construction Program (2013)

Science and Technology Planning Project of Zhejiang Province of China

Zhejiang Administration of Traditional Chinese Medicine Foundation

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1759-7714.12496/fullpdf

Reference24 articles.

1. Cancer statistics, 2017;Siegel;CA Cancer J Clin,2017

2. Cancer treatment and survivorship statistics, 2014;DeSantis;CA Cancer J Clin,2014

3. The pivotal role of pathology in the management of lung cancer;Davidson;J Thorac Dis,2013

4. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

5. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy;Paez;Science,2004

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer;Molecular Cancer Research;2022-02-11

2. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1‐ALK fusion;Thoracic Cancer;2021-12-28

3. Biosensors for Point Mutation Detection;Frontiers in Bioengineering and Biotechnology;2021-12-15

4. Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib;Clinical Cancer Research;2021-09-22

5. Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer;Trends in Cancer;2021-05